文献库搜索 | GeneLibs

Gleeson(Ferga C),Kipp(Benjamin R),Voss(Jes... Gastrointest Endosc 2016-06-20

...PIK3CA (n = 4; 5.3%), SMAD4 (n = 3; 3.9%), and BRAF (n = 3; 3.9%). Pathogenic alterations were identified in the MAPK an...

Kofuji(Satoshi),Kimura(Hirotaka),Nakanishi... Cancer Discov 2016-04-21

...PIK3CA-activated cancers.,Although INPP4B expression is reduced in several types of human cancers, our work on Inpp4B-de...

Ma(Brigette B),Mo(Frankie),Tong(Joanna H),... Asia Pac J Clin Oncol 2016-04-14

The prognostic significance of KRAS, NRAS, PIK3CA and BRAF mutations was evaluated in Chinese patients with metastatic c...

Liu(Suqin),Wang(Hongjiang),Zhang(Lizhi),Ta... Hum Genomics 2016-01-08

...PIK3CA and TP53, infrequent mutations in PTEN, and uncommon combination mutations in luminal-type cancers in other genes...

Miura(John T),Xiu(Joanne),Thomas(James),Ge... Cancer Biol Ther 2016-03-01

...PIK3CA (5.1%). IHC of TOP2A was high in 76% of cases, TOPO1 in 51% and SPARC in 25%; low IHC of ERCC1 was seen in 65%, R...

Levin(Maren K),Wang(Kai),Yelensky(Roman),C... Cancer Med 2016-05-05

...PIK3CA, amplifications of FGFR1 or ZNF703, or phosphorylation of HER family receptors and their downstream proteins did ...

Li(Xiaolei),Tao(Junyan),Cigliano(Antonio),... Oncotarget 2016-04-05

...PIK3CA (PIK3CAH1047R) and Yap (YapS127A) in the mouse liver using hydrodynamic transfection (PIK3CA/Yap). In addition, s...

Hanusch(Claus),Schneeweiss(Andreas),Loibl(... Clin Cancer Res 2016-04-19

...PIK3CA tumor mutations (P = 0.363). Clinical responses were seen in 96.3% of 54 evaluable patients, and breast conservin...

Takenaka(Masataka),Saito(Motonobu),Iwakawa... Int J Oncol 2016-01-26

...PIK3CA (25.0%), KRAS (13.9%), ERBB2 (4.3%), PTEN (2.8%), RB1 (2.8%), CDKN2A (2.8%), AKT1 (1.4%), CTNNB1 (1.4%) and NRAS ...

Nuciforo(P G),Aura(C),Holmes(E),Prudkin(L)... Ann Oncol 2016-04-05

...PIK3CA mutation) with total pathological complete response (tpCR) at surgery, event-free survival (EFS), and overall sur...